- Sun Pharmaceutical Industries Limited announces successful results from Phase 3 clinical studies of tildrakizumab (ILUMYA) for active psoriatic arthritis.
- Both INSPIRE-1 and INSPIRE-2…
Join the vibrant privacy-ensured Dzambhala community on
Want to give feedback on this story? Write to us at [email protected]